Tag: global pharmacovigilance market

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

#Pharmacovigilance Market Revenue Outlook: What CAGR Lies Ahead Through 2030?#_x000D_

The pharmacovigilance market size has experienced rapid growth in recent years. It is anticipated to expand from $9.64 billion in 2025 to $10.86 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 12.7%. The expansion observed in the historic period can be attributed to increasing adverse drug reaction reporting, expansion of global pharmaceutical approvals, rising clinical trial volumes, establishment of international drug safety regulations, and growth in chronic disease drug usage._x000D_

_x000D_

The pharmacovigilance market is anticipated to undergo significant expansion in the coming years, with its size projected to reach $17.41 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 12.5%. This growth during the forecast period is attributed to several factors, including the increasing utilization of real-world data, a rise in approvals for biologics and biosimilars, the escalating complexity of combination therapies, the expansion of pharmacovigilance activities into emerging markets, and a heightened focus on patient safety outcomes. Prominent trends expected in this period encompass the broadening of post-marketing surveillance efforts, a growing reliance on real-world evidence in safety monitoring, more rigorous regulatory oversight and compliance demands, an increase in the outsourcing of pharmacovigilance services, and the integration of diverse safety data platforms._x000D_

_x000D_

#Get A Free Sample Report With In-Depth Market Insights:#_x000D_

https://thebusinessresearchcompany.com/sample_request?id=43491693&type=smp&name=Pharmacovigilance%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Pharmacovigilance Market Demand Drivers: What’s Powering Industry Growth?#_x000D_

Elevated levels of research and development undertakings are projected to fuel the expansion of the pharmacovigilance market. Through strategic investment in R&D, pharmaceutical firms are able to create novel and cutting-edge medications featuring enhanced safety profiles. Thorough preclinical and clinical evaluations conducted throughout the drug development cycle facilitate the prompt detection of possible safety issues, thereby enabling the deployment of suitable risk mitigation tactics. Furthermore, R&D initiatives contribute significantly to the progression of technologies utilized for adverse event surveillance, data analytics, and signal identification, thus aiding the swift discovery of adverse drug reactions during the post-marketing period. As an illustration, in 2023, data from the Office for National Statistics, a UK-based government agency, showed that the UK government’s net expenditure on research and development (R&D) climbed to £17.4 billion in 2023, an increase from £16.1 billion in 2022, representing an 8.2% rise. Consequently, the heightened engagement in research and development activities has effectively bolstered the expansion of the pharmacovigilance market._x000D_

_x000D_

#Pharmacovigilance Market Segment Outlook: Which Categories Are Growing Fastest?#_x000D_

The pharmacovigilance market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining_x000D_

2) By Service Provider: In-House, Contract Outsourcing_x000D_

3) By Process Flow: Case Data Management, Signal Detection, Risk Management System_x000D_

4) By Clinical Trial Phases: Preclinical, Phase I, Phase II, Phase III, Phase IV_x000D_

5) By End User: Hospitals, Pharmaceutical Companies, Other End Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Spontaneous Reporting: Individual Case Safety Reports (ICSRs), Voluntary Reporting Systems, Case Reports From Healthcare Professionals _x000D_

2) By Intensified ADR Reporting: Active Surveillance Programs, Enhanced Monitoring In Clinical Trials, Risk Minimization Strategies _x000D_

3) By Targeted Spontaneous Reporting: Reporting For Specific Drug Classes, Condition-Specific Reporting, Focused Surveillance Programs _x000D_

4) By Cohort Event Monitoring: Prospective Cohort Studies, Retrospective Cohort Studies, Longitudinal Studies _x000D_

5) By EHR Mining: Data Extraction From Electronic Health Records, Signal Detection Through EHR Analysis, Integration Of EHR Data With Pharmacovigilance Systems _x000D_

_x000D_

#Pharmacovigilance Market Innovation Trends: What Developments Are Reshaping The Industry?#_x000D_

Leading companies within the pharmacovigilance market are increasingly concentrating on artificial intelligence (AI) to enhance their operational efficiency. AI has the potential to boost the effectiveness and precision of pharmacovigilance activities, ultimately resulting in improved patient outcomes. By leveraging AI, pharmaceutical firms can streamline their operations, optimize data management, and accelerate drug discovery, concurrently lowering costs and increasing safety. For example, in August 2024, the Government of India introduced the Adverse Drug Reaction Monitoring System (ADRMS) software, launched by the Minister of Health & Family Welfare and Minister of Chemicals and Fertilizers. This pharmacovigilance software assists in the collection and analysis of adverse events associated with medicines and medical devices, thereby simplifying the reporting process for both consumers and healthcare professionals. This initiative considerably strengthens India’s pharmacovigilance infrastructure by ensuring a more extensive capture of safety data and elevating drug safety monitoring. The ADRMS endeavors to improve the efficiency of drug safety oversight and adherence to standards, thereby helping to establish India as a prominent player in the global pharmaceutical industry._x000D_

_x000D_

#Pharmacovigilance Market Leading Companies And Competitive Benchmarking#_x000D_

Major companies operating in the pharmacovigilance market are IQVIA, Cognizant, ICON Plc, Accenture plc, PAREXEL International Corporation, United BioSource LLC, ArisGlobal, Quanticate, Wipro Limited, Linical Americas, Novotech CRO, EXTEDO, Arriello, PrimeVigilance, Axios International, C3i Solutions, Secure AI Labs, OmniSol dot Tech, Prevnos Inc., Lifescient Inc, QuintilesIMS, Labcorp Drug Development, Pharmaceutical Product Development Inc., PRA Health Sciences, Synowledge LLC, RAPAhub, illuminate health, Invenio Medical, ClinChoice Inc., Novasyte, Fortrea Holdings Inc., Syneos Health Clinical, Telerx Marketing Inc. _x000D_

_x000D_

#View The Full Pharmacovigilance Market Report:#_x000D_

https://thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Pharmacovigilance Market Regional Analysis And Top Geography#_x000D_

North America was the largest region in the pharmacovigilance market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast region. The regions covered in the pharmacovigilance market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Reach Out To Our Team:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas: +1 310-496-7795_x000D_

Asia: +44 7882 955267 & +91 8897263534_x000D_

Europe: +44 7882 955267_x000D_

Email us at: marketing@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Pharmacovigilance Market Value Expansion And Long-Term Growth Outlook

The pharmacovigilance sector has experienced swift expansion over the last few years, advancing from a valuation of $9.64 billion in 2025 to an estimated $10.86 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.7%. This upward trajectory during the historical phase is largely driven by heightened adverse drug reaction reporting, a broader scope of pharmaceutical approvals worldwide, an uptick in clinical trial activities, the development of global drug safety standards, and increased consumption of medications for chronic conditions.

The pharmacovigilance market is forecast to experience significant growth over the coming years, with projections indicating it will reach a value of $17.41 billion by 2030, expanding at a compound annual growth rate (CAGR) of 12.5%. This anticipated expansion during the forecast period is driven by factors such as the increased use of real-world data, a rise in approvals for biologics and biosimilars, the growing complexity of combination therapies, the broadening of pharmacovigilance activities within emerging markets, and a heightened emphasis on patient safety outcomes. Key developments expected in this period include the broadening of post-marketing surveillance initiatives, a greater reliance on real-world evidence for safety monitoring, tighter regulatory oversight and adherence requirements, a rising trend toward outsourcing pharmacovigilance services, and the merging of safety data from multiple sources.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5928&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Pharmacovigilance Market Expansion Drivers: What Is Shaping Future Growth?

The pharmacovigilance market is being fuelled by an increase in research and development activities. Through investment in R&D, pharmaceutical companies are able to create new and innovative drugs that feature enhanced safety profiles. Potential safety issues are identified early on through rigorous preclinical and clinical testing conducted during the drug development process, which enables the implementation of suitable risk mitigation strategies. Furthermore, R&D efforts contribute to progress in technologies designed for adverse event monitoring, data analysis, and signal detection, making it easier to spot adverse drug reactions early in the post-marketing phase. As an example, in 2023, the Office for National Statistics, a UK-based government agency, reported that the UK government’s net R&D spending rose to £17.4 billion from £16.1 billion in 2022, representing an 8.2% increase. Consequently, the growth of the pharmacovigilance market was supported by these expanding research and development activities.

Pharmacovigilance Market Segmentation And Category Breakdown

The pharmacovigilance market covered in this report is segmented –

1) By Type: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining

2) By Service Provider: In-House, Contract Outsourcing

3) By Process Flow: Case Data Management, Signal Detection, Risk Management System

4) By Clinical Trial Phases: Preclinical, Phase I, Phase II, Phase III, Phase IV

5) By End User: Hospitals, Pharmaceutical Companies, Other End Users

Subsegments:

1) By Spontaneous Reporting: Individual Case Safety Reports (ICSRs), Voluntary Reporting Systems, Case Reports From Healthcare Professionals

2) By Intensified ADR Reporting: Active Surveillance Programs, Enhanced Monitoring In Clinical Trials, Risk Minimization Strategies

3) By Targeted Spontaneous Reporting: Reporting For Specific Drug Classes, Condition-Specific Reporting, Focused Surveillance Programs

4) By Cohort Event Monitoring: Prospective Cohort Studies, Retrospective Cohort Studies, Longitudinal Studies

5) By EHR Mining: Data Extraction From Electronic Health Records, Signal Detection Through EHR Analysis, Integration Of EHR Data With Pharmacovigilance Systems

Pharmacovigilance Market Strategic Trends: What Is Defining The Next Phase Of Growth?

Key players in the pharmacovigilance market are increasingly turning to artificial intelligence (AI) to boost operational efficiency. By enhancing both the precision and speed of pharmacovigilance tasks, AI contributes to improved patient safety outcomes. Pharmaceutical firms leverage this technology to refine their workflows, enhance data handling, speed up drug development, and cut expenses while strengthening safety protocols. A notable example occurred in August 2024, when India’s government unveiled the Adverse Drug Reaction Monitoring System (ADRMS) software, introduced by the Minister of Health & Family Welfare along with the Minister of Chemicals and Fertilizers. This pharmacovigilance tool enables the gathering and analysis of adverse events linked to medications and medical devices, simplifying reporting for consumers and healthcare workers alike. Such an initiative greatly bolsters India’s pharmacovigilance framework by enabling more thorough safety data collection and reinforcing drug safety oversight. The ADRMS is intended to elevate the effectiveness of drug safety compliance and regulatory standards, thereby positioning India as a frontrunner in the worldwide pharmaceutical sector.

Pharmacovigilance Market Competitive Analysis Of Major Industry Participants

Major companies operating in the pharmacovigilance market are IQVIA, Cognizant, ICON Plc, Accenture plc, PAREXEL International Corporation, United BioSource LLC, ArisGlobal, Quanticate, Wipro Limited, Linical Americas, Novotech CRO, EXTEDO, Arriello, PrimeVigilance, Axios International, C3i Solutions, Secure AI Labs, OmniSol dot Tech, Prevnos Inc., Lifescient Inc, QuintilesIMS, Labcorp Drug Development, Pharmaceutical Product Development Inc., PRA Health Sciences, Synowledge LLC, RAPAhub, illuminate health, Invenio Medical, ClinChoice Inc., Novasyte, Fortrea Holdings Inc., Syneos Health Clinical, Telerx Marketing Inc.

Access The Complete Pharmacovigilance Market Report:

https://www.thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Pharmacovigilance Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the pharmacovigilance market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast region. The regions covered in the pharmacovigilance market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Pharmacovigilance Market Increase Between 2026 And 2030?

The pharmacovigilance market size has shown rapid expansion in recent years. Its value is anticipated to increase from $9.64 billion in 2025 to $10.86 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.7%. Historically, this market’s growth has been fueled by an increase in adverse drug reaction reporting, wider global pharmaceutical approvals, a rise in clinical trial volumes, the establishment of international drug safety regulations, and greater usage of drugs for chronic diseases.

The pharmacovigilance market is projected to experience substantial expansion over the upcoming years. By 2030, its valuation is anticipated to reach $17.41 billion, driven by a compound annual growth rate (CAGR) of 12.5%. This expansion during the projection period stems from factors such as increased use of real-world data, a rise in approvals for biologics and biosimilars, the growing intricacy of combination therapies, the widening scope of pharmacovigilance in developing regions, and a heightened emphasis on patient safety results. Key developments expected during this timeframe involve the broadening of post-marketing surveillance, a greater uptake of real-world evidence in safety assessments, intensified regulatory oversight and adherence demands, an increase in the outsourcing of pharmacovigilance functions, and the consolidation of safety data from multiple sources.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5928&type=smp

Which Growth Drivers Are Expected To Support The Pharmacovigilance Market Forward?

Rising research and development endeavors are set to propel the pharmacovigilance market. Through investments in R&D, pharmaceutical firms are able to create novel and advanced medications possessing enhanced safety characteristics. Thorough preclinical and clinical trials conducted during the drug development lifecycle facilitate the prompt identification of possible safety issues, enabling the deployment of suitable risk reduction strategies. Moreover, R&D initiatives aid in evolving technologies for tracking adverse events, analyzing data, and identifying signals, thereby assisting in the swift detection of undesirable drug reactions post-marketing. For example, in 2023, the Office for National Statistics, a UK-based government agency, reported that the UK government’s net expenditure on research and development (R&D) climbed to £17.4 billion in 2023, an increase from £16.1 billion in 2022, signifying an 8.2% surge. Consequently, the escalating research and development activities have bolstered the expansion of the pharmacovigilance market.

Which Segment Groups Define The Pharmacovigilance Market Landscape?

The pharmacovigilance market covered in this report is segmented –

1) By Type: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining

2) By Service Provider: In-House, Contract Outsourcing

3) By Process Flow: Case Data Management, Signal Detection, Risk Management System

4) By Clinical Trial Phases: Preclinical, Phase I, Phase II, Phase III, Phase IV

5) By End User: Hospitals, Pharmaceutical Companies, Other End Users

Subsegments:

1) By Spontaneous Reporting: Individual Case Safety Reports (ICSRs), Voluntary Reporting Systems, Case Reports From Healthcare Professionals

2) By Intensified ADR Reporting: Active Surveillance Programs, Enhanced Monitoring In Clinical Trials, Risk Minimization Strategies

3) By Targeted Spontaneous Reporting: Reporting For Specific Drug Classes, Condition-Specific Reporting, Focused Surveillance Programs

4) By Cohort Event Monitoring: Prospective Cohort Studies, Retrospective Cohort Studies, Longitudinal Studies

5) By EHR Mining: Data Extraction From Electronic Health Records, Signal Detection Through EHR Analysis, Integration Of EHR Data With Pharmacovigilance Systems

What Trends Are Affecting The Pharmacovigilance Market Dynamics?

Leading companies within the pharmacovigilance market are increasingly directing their focus towards artificial intelligence (AI) to enhance operational efficiency. AI is instrumental in boosting the effectiveness and precision of pharmacovigilance activities, ultimately contributing to improved patient outcomes. By integrating AI, pharmaceutical enterprises can streamline their processes, refine data management, and accelerate drug discovery, concurrently achieving cost reductions and heightened safety. An illustrative example occurred in August 2024, when the Government of India introduced the Adverse Drug Reaction Monitoring System (ADRMS) software, launched by the Minister of Health & Family Welfare and Minister of Chemicals and Fertilizers. This specialized pharmacovigilance software facilitates the systematic gathering and analysis of adverse events associated with medicines and medical devices, thereby simplifying the reporting process for both consumers and healthcare professionals. This endeavor considerably fortifies India’s pharmacovigilance infrastructure by ensuring a more thorough acquisition of safety data and elevating drug safety monitoring. The ADRMS is designed to improve the efficiency of drug safety oversight and compliance with established standards, aiming to position India as a pivotal leader in the global pharmaceutical industry.

Which Organizations Are Involved In The Pharmacovigilance Market?

Major companies operating in the pharmacovigilance market are IQVIA, Cognizant, ICON Plc, Accenture plc, PAREXEL International Corporation, United BioSource LLC, ArisGlobal, Quanticate, Wipro Limited, Linical Americas, Novotech CRO, EXTEDO, Arriello, PrimeVigilance, Axios International, C3i Solutions, Secure AI Labs, OmniSol dot Tech, Prevnos Inc., Lifescient Inc, QuintilesIMS, Labcorp Drug Development, Pharmaceutical Product Development Inc., PRA Health Sciences, Synowledge LLC, RAPAhub, illuminate health, Invenio Medical, ClinChoice Inc., Novasyte, Fortrea Holdings Inc., Syneos Health Clinical, Telerx Marketing Inc.

Access The Complete Pharmacovigilance Market Report:

https://www.thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report

What Is The Largest Regional Market In The Pharmacovigilance Market?

North America was the largest region in the pharmacovigilance market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast region. The regions covered in the pharmacovigilance market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Pharmacovigilance Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=5928&type=smp

Browse Through More Reports Similar to the Global Pharmacovigilance Market 2026, By The Business Research Company

Pharmacovigilance Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report

Medical Devices Vigilance Market Report 2026

https://www.thebusinessresearchcompany.com/report/medical-devices-vigilance-global-market-report

Cosmetovigilance Market Report 2026

https://www.thebusinessresearchcompany.com/report/cosmetovigilance-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Pharmacovigilance Market During The Forecast Period?

The pharmacovigilance market has experienced substantial growth in recent years. It is forecast to grow from $9.64 billion in 2025 to $10.86 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.7%. The expansion witnessed in previous periods is largely attributable to factors such as increasing adverse drug reaction reporting, the broader reach of global pharmaceutical approvals, rising clinical trial volumes, the establishment of international drug safety regulations, and the growing usage of drugs for chronic diseases.

The pharmacovigilance market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $17.41 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.5%. This projected growth during the forecast period is largely driven by factors such as the increased use of real-world data, a rise in approvals for biologics and biosimilars, the growing intricacy of combination therapies, the broadening scope of pharmacovigilance in developing regions, and a heightened emphasis on patient safety results. Key trends expected during this period involve the expansion of post-marketing surveillance efforts, the increasing embrace of real-world evidence for safety monitoring, stricter regulatory oversight and compliance demands, the growing practice of outsourcing pharmacovigilance services, and the consolidation of safety data from multiple sources into integrated platforms.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5928&type=smp

Which Major Drivers Are Influencing The Expansion Of The Pharmacovigilance Market?

The escalating research and development activities are poised to propel the pharmacovigilance market. By allocating resources to R&D, pharmaceutical companies can devise novel and advanced medications featuring enhanced safety profiles. Thorough preclinical and clinical assessments during the drug development phase enable the prompt identification of potential safety issues, allowing for the implementation of appropriate risk mitigation strategies. Moreover, R&D initiatives contribute to the enhancement of technologies for adverse event monitoring, data analysis, and signal detection, thereby facilitating the early discovery of adverse drug reactions in the post-marketing period. For instance, in 2023, according to the Office for National Statistics, a UK-based, government agency, the UK government’s net spending on research and development (R&D) increased to £17.4 billion in 2023, up from £16.1 billion in 2022, marking an 8.2% rise. Consequently, the increasing research and development endeavors have supported the growth of the pharmacovigilance market.

How Is Segmentation Applied In The Pharmacovigilance Market Segment Analysis?

The pharmacovigilance market covered in this report is segmented –

1) By Type: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining

2) By Service Provider: In-House, Contract Outsourcing

3) By Process Flow: Case Data Management, Signal Detection, Risk Management System

4) By Clinical Trial Phases: Preclinical, Phase I, Phase II, Phase III, Phase IV

5) By End User: Hospitals, Pharmaceutical Companies, Other End Users

Subsegments:

1) By Spontaneous Reporting: Individual Case Safety Reports (ICSRs), Voluntary Reporting Systems, Case Reports From Healthcare Professionals

2) By Intensified ADR Reporting: Active Surveillance Programs, Enhanced Monitoring In Clinical Trials, Risk Minimization Strategies

3) By Targeted Spontaneous Reporting: Reporting For Specific Drug Classes, Condition-Specific Reporting, Focused Surveillance Programs

4) By Cohort Event Monitoring: Prospective Cohort Studies, Retrospective Cohort Studies, Longitudinal Studies

5) By EHR Mining: Data Extraction From Electronic Health Records, Signal Detection Through EHR Analysis, Integration Of EHR Data With Pharmacovigilance Systems

Which Trends Are Influencing Demand In The Pharmacovigilance Market?

Leading companies in the pharmacovigilance market are increasingly concentrating on artificial intelligence (AI) to boost their operational efficiency. AI has the capability to enhance the effectiveness and precision of pharmacovigilance activities, ultimately leading to improved patient outcomes. By leveraging AI, pharmaceutical firms can optimize their workflows, refine data management, and accelerate drug discovery, while simultaneously cutting costs and elevating safety standards. For instance, in August 2024, the Government of India rolled out the Adverse Drug Reaction Monitoring System (ADRMS) software, introduced by the Minister of Health & Family Welfare and Minister of Chemicals and Fertilizers. This pharmacovigilance software aids in the collection and examination of adverse events associated with medicines and medical devices, simplifying the reporting process for both consumers and healthcare professionals. This initiative substantially reinforces India’s pharmacovigilance infrastructure by ensuring a more extensive capture of safety data and strengthening drug safety monitoring. The ADRMS aims to improve the efficiency of drug safety oversight and compliance with standards, thereby helping to position India as a key player in the global pharmaceutical industry.

Who Are The Companies Participating In The Pharmacovigilance Market Environment?

Major companies operating in the pharmacovigilance market are IQVIA, Cognizant, ICON Plc, Accenture plc, PAREXEL International Corporation, United BioSource LLC, ArisGlobal, Quanticate, Wipro Limited, Linical Americas, Novotech CRO, EXTEDO, Arriello, PrimeVigilance, Axios International, C3i Solutions, Secure AI Labs, OmniSol dot Tech, Prevnos Inc., Lifescient Inc, QuintilesIMS, Labcorp Drug Development, Pharmaceutical Product Development Inc., PRA Health Sciences, Synowledge LLC, RAPAhub, illuminate health, Invenio Medical, ClinChoice Inc., Novasyte, Fortrea Holdings Inc., Syneos Health Clinical, Telerx Marketing Inc.

Get The Full Pharmacovigilance Market Report:

https://www.thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report

Which Region Has The Greatest Market Share In The Pharmacovigilance Market?

North America was the largest region in the pharmacovigilance market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast region. The regions covered in the pharmacovigilance market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Pharmacovigilance Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report

Browse Through More Reports Similar to the Global Pharmacovigilance Market 2026, By The Business Research Company

Pharmacovigilance Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report

Medical Devices Vigilance Market Report 2026

https://www.thebusinessresearchcompany.com/report/medical-devices-vigilance-global-market-report

Cosmetovigilance Market Report 2026

https://www.thebusinessresearchcompany.com/report/cosmetovigilance-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Pharmacovigilance Market By The End Of 2030?

The pharmacovigilance market has experienced swift expansion recently. Its valuation is set to climb from $9.64 billion in 2025 to $10.86 billion in 2026, driven by a compound annual growth rate (CAGR) of 12.7%. Historically, this growth has stemmed from factors such as a rise in adverse drug reaction reporting, a broader scope of global pharmaceutical approvals, an increase in clinical trial volumes, the implementation of international drug safety regulations, and greater drug usage for chronic diseases.

The pharmacovigilance market is set to experience significant expansion in the upcoming years. Its valuation is projected to reach $17.41 billion by 2030, progressing at a compound annual growth rate (CAGR) of 12.5%. This anticipated growth is influenced by factors such as the increasing utilization of real-world data, the growing number of approvals for biologics and biosimilars, the rising complexity of combination therapies, the spread of pharmacovigilance practices in emerging markets, and an enhanced focus on patient safety outcomes. Prominent trends for this period include the scaling up of post-marketing surveillance activities, the wider adoption of real-world evidence in safety monitoring, more stringent regulatory scrutiny and compliance requirements, an increase in the outsourcing of pharmacovigilance services, and the consolidation of multisource safety data platforms.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5928&type=smp

Which Market Drivers Are Supporting The Expansion Of The Pharmacovigilance Market?

Heightened research and development efforts are anticipated to propel the pharmacovigilance market. By allocating resources to R&D, pharmaceutical companies can formulate novel and advanced drugs with superior safety profiles. Rigorous preclinical and clinical assessments during the drug development lifecycle facilitate the early recognition of potential safety concerns, allowing for the implementation of appropriate risk mitigation strategies. Moreover, R&D endeavors advance technologies for monitoring adverse events, analyzing data, and detecting signals, thereby facilitating the swift identification of adverse drug reactions in the post-marketing stage. For instance, in 2023, according to Office for National Statistics, a UK-based, government agency, the UK government’s net spending on research and development (R&D) increased to £17.4 billion in 2023, up from £16.1 billion in 2022, marking an 8.2% rise. Consequently, the expanding research and development activities have supported the growth of the pharmacovigilance market.

Which Segment Classifications Shape The Pharmacovigilance Market?

The pharmacovigilance market covered in this report is segmented –

1) By Type: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining

2) By Service Provider: In-House, Contract Outsourcing

3) By Process Flow: Case Data Management, Signal Detection, Risk Management System

4) By Clinical Trial Phases: Preclinical, Phase I, Phase II, Phase III, Phase IV

5) By End User: Hospitals, Pharmaceutical Companies, Other End Users

Subsegments:

1) By Spontaneous Reporting: Individual Case Safety Reports (ICSRs), Voluntary Reporting Systems, Case Reports From Healthcare Professionals

2) By Intensified ADR Reporting: Active Surveillance Programs, Enhanced Monitoring In Clinical Trials, Risk Minimization Strategies

3) By Targeted Spontaneous Reporting: Reporting For Specific Drug Classes, Condition-Specific Reporting, Focused Surveillance Programs

4) By Cohort Event Monitoring: Prospective Cohort Studies, Retrospective Cohort Studies, Longitudinal Studies

5) By EHR Mining: Data Extraction From Electronic Health Records, Signal Detection Through EHR Analysis, Integration Of EHR Data With Pharmacovigilance Systems

How Are Trends Impacting The Pharmacovigilance Market?

Leading entities within the pharmacovigilance market are increasingly directing their attention towards artificial intelligence (AI) as a means to enhance operational efficiency. AI possesses the capability to boost the effectiveness and precision of pharmacovigilance tasks, thereby contributing to superior patient results. Through the deployment of AI, pharmaceutical firms can optimize their workflows, refine data handling, and expedite the drug discovery process, all while simultaneously cutting expenditures and bolstering safety measures. An illustrative example occurred in August 2024, when the Government of India rolled out the Adverse Drug Reaction Monitoring System (ADRMS) software, unveiled by the Minister of Health & Family Welfare and Minister of Chemicals and Fertilizers. This specific pharmacovigilance software simplifies the gathering and examination of negative occurrences associated with medicines and medical apparatus, thereby streamlining the reporting procedure for both end-users and medical practitioners. This undertaking considerably reinforces India’s pharmacovigilance framework by guaranteeing a more thorough acquisition of safety information and elevating the oversight of drug safety. The ADRMS is designed to elevate the effectiveness of drug safety supervision and adherence to regulatory benchmarks, aiding in establishing India as a prominent player in the worldwide pharmaceutical sector.

Which Companies Are Expanding Their Footprint In The Pharmacovigilance Market?

Major companies operating in the pharmacovigilance market are IQVIA, Cognizant, ICON Plc, Accenture plc, PAREXEL International Corporation, United BioSource LLC, ArisGlobal, Quanticate, Wipro Limited, Linical Americas, Novotech CRO, EXTEDO, Arriello, PrimeVigilance, Axios International, C3i Solutions, Secure AI Labs, OmniSol dot Tech, Prevnos Inc., Lifescient Inc, QuintilesIMS, Labcorp Drug Development, Pharmaceutical Product Development Inc., PRA Health Sciences, Synowledge LLC, RAPAhub, illuminate health, Invenio Medical, ClinChoice Inc., Novasyte, Fortrea Holdings Inc., Syneos Health Clinical, Telerx Marketing Inc.

Read the full pharmacovigilance market report here:

https://www.thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report

How Is The Pharmacovigilance Market Distributed Across Key Geographic Regions?

North America was the largest region in the pharmacovigilance market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast region. The regions covered in the pharmacovigilance market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Pharmacovigilance Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=5928&type=smp

Browse Through More Reports Similar to the Global Pharmacovigilance Market 2026, By The Business Research Company

Pharmacovigilance Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report

Medical Devices Vigilance Market Report 2026

https://www.thebusinessresearchcompany.com/report/medical-devices-vigilance-global-market-report

Cosmetovigilance Market Report 2026

https://www.thebusinessresearchcompany.com/report/cosmetovigilance-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the pharmacovigilance market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Pharmacovigilance Market reach by 2030 starting from 2026 levels?

The pharmacovigilance market size has seen rapid expansion in recent years. It is anticipated to increase from $9.64 billion in 2025 to $10.86 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.7%. The historical growth of this market can be attributed to several factors, including a rise in adverse drug reaction reporting, the broadening of global pharmaceutical approvals, an increase in clinical trial volumes, the establishment of international drug safety regulations, and the growing usage of drugs for chronic diseases.

The pharmacovigilance market is projected to experience substantial expansion over the coming years, reaching $17.41 billion by 2030, driven by a compound annual growth rate (CAGR) of 12.5%. This anticipated growth during the forecast period is fueled by several factors, including the increased use of real-world data, a rise in approvals for biologics and biosimilars, the growing intricacy of combination therapies, the expansion of pharmacovigilance activities in developing economies, and a heightened emphasis on patient safety results. Key trends anticipated during this period encompass the broadening of post-marketing surveillance efforts, the increasing incorporation of real-world evidence into safety monitoring, intensified regulatory oversight and adherence demands, a surge in the outsourcing of pharmacovigilance services, and the merging of multisource safety data platforms.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5928&type=smp

Which Drivers Are Influencing Long-Term Growth In The Pharmacovigilance Market?

The expansion of research and development endeavors is poised to stimulate the pharmacovigilance market. By allocating resources to R&D, pharmaceutical enterprises are able to formulate new and innovative medicines with superior safety profiles. Rigorous testing carried out during the preclinical and clinical stages of drug development facilitates the early identification of potential safety concerns, allowing for the implementation of appropriate risk mitigation plans. Moreover, R&D efforts contribute to the advancement of techniques for monitoring adverse events, analyzing data, and detecting signals, which in turn supports the prompt discovery of adverse drug reactions in the post-marketing phase. For instance, in 2023, according to Office for National Statistics, a UK-based, government agency, the UK government’s net spending on research and development (R&D) increased to £17.4 billion in 2023, up from £16.1 billion in 2022, marking an 8.2% rise. Thus, the escalating research and development activities have underpinned the expansion of the pharmacovigilance market.

Which Segments Are Driving Activity In The Pharmacovigilance Market?

The pharmacovigilance market covered in this report is segmented –

1) By Type: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining

2) By Service Provider: In-House, Contract Outsourcing

3) By Process Flow: Case Data Management, Signal Detection, Risk Management System

4) By Clinical Trial Phases: Preclinical, Phase I, Phase II, Phase III, Phase IV

5) By End User: Hospitals, Pharmaceutical Companies, Other End Users

Subsegments:

1) By Spontaneous Reporting: Individual Case Safety Reports (ICSRs), Voluntary Reporting Systems, Case Reports From Healthcare Professionals

2) By Intensified ADR Reporting: Active Surveillance Programs, Enhanced Monitoring In Clinical Trials, Risk Minimization Strategies

3) By Targeted Spontaneous Reporting: Reporting For Specific Drug Classes, Condition-Specific Reporting, Focused Surveillance Programs

4) By Cohort Event Monitoring: Prospective Cohort Studies, Retrospective Cohort Studies, Longitudinal Studies

5) By EHR Mining: Data Extraction From Electronic Health Records, Signal Detection Through EHR Analysis, Integration Of EHR Data With Pharmacovigilance Systems

What Long-Term Trends Are Expected To Shape The Future Of The Pharmacovigilance Market?

Leading enterprises within the pharmacovigilance market are increasingly leveraging artificial intelligence (AI) to enhance their operational effectiveness. AI has the capacity to boost both the efficiency and precision of pharmacovigilance operations, ultimately contributing to superior patient results. Through the deployment of AI, pharmaceutical firms can optimize workflows, refine data handling, and expedite drug discovery, all while simultaneously cutting expenses and elevating safety standards. As an illustration, in August 2024, the Government of India rolled out the Adverse Drug Reaction Monitoring System (ADRMS) software, which was unveiled by the Minister of Health & Family Welfare and Minister of Chemicals and Fertilizers. This dedicated pharmacovigilance software aids in the gathering and examination of adverse events linked to pharmaceuticals and medical apparatus, thereby simplifying the reporting mechanism for both end-users and medical practitioners. This undertaking substantially bolsters India’s pharmacovigilance framework by guaranteeing a more exhaustive collection of safety data and augmenting drug safety surveillance. The ADRMS seeks to elevate the effectiveness of drug safety supervision and adherence to regulations, thereby assisting India in establishing itself as a frontrunner in the worldwide pharmaceutical sector.

Which Leading Companies Dominate The Pharmacovigilance Market Share?

Major companies operating in the pharmacovigilance market are IQVIA, Cognizant, ICON Plc, Accenture plc, PAREXEL International Corporation, United BioSource LLC, ArisGlobal, Quanticate, Wipro Limited, Linical Americas, Novotech CRO, EXTEDO, Arriello, PrimeVigilance, Axios International, C3i Solutions, Secure AI Labs, OmniSol dot Tech, Prevnos Inc., Lifescient Inc, QuintilesIMS, Labcorp Drug Development, Pharmaceutical Product Development Inc., PRA Health Sciences, Synowledge LLC, RAPAhub, illuminate health, Invenio Medical, ClinChoice Inc., Novasyte, Fortrea Holdings Inc., Syneos Health Clinical, Telerx Marketing Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report

How Does The Pharmacovigilance Market Perform Across Major Global Regions?

North America was the largest region in the pharmacovigilance market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast region. The regions covered in the pharmacovigilance market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pharmacovigilance Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=5928&type=smp

Browse Through More Reports Similar to the Global Pharmacovigilance Market 2026, By The Business Research Company

Pharmacovigilance Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report

Medical Devices Vigilance Market Report 2026

https://www.thebusinessresearchcompany.com/report/medical-devices-vigilance-global-market-report

Cosmetovigilance Market Report 2026

https://www.thebusinessresearchcompany.com/report/cosmetovigilance-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the pharmacovigilance market from 2025–2034 with trusted insights from The Business Research Company

What Is The Present Size Of The Pharmacovigilance Market And What Value Is Projected For 2029?

The pharmacovigilance market has experienced swift expansion in recent years. It is projected to increase from $8.58 billion in 2024 to $9.64 billion in 2025, achieving a compound annual growth rate (CAGR) of 12.4%. This historical growth can be attributed to the increasing incidence of adverse drug reactions (ADRs), heightened research and development (R&D) activities, growing drug development rates, an increasing focus on personalized medicine, and the rising prevalence of chronic diseases.

The pharmacovigilance market is projected to experience swift expansion over the coming years. This market is anticipated to reach $15.5 billion by 2029, achieving a compound annual growth rate (CAGR) of 12.6%. Factors contributing to this growth during the forecast period include increasing healthcare spending, greater governmental backing, and the expanding elderly demographic. Key trends identified for this period encompass heightened investments, the adoption of artificial intelligence, the utilization of cutting-edge platforms, the deployment of innovative cloud-based systems, and strategic consolidations and acquisitions.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5928&type=smp

What Factors Are Boosting The Pharmacovigilance Market?

Elevated levels of research and development endeavors are projected to propel the pharmacovigilance market forward. Through capital injection into R&D, pharmaceutical firms are empowered to create novel and cutting-edge medications featuring enhanced safety characteristics. Thorough preclinical and clinical assessments conducted throughout drug formulation facilitate the prompt detection of possible safety issues, thereby enabling the deployment of suitable risk reduction measures. Furthermore, R&D initiatives contribute to progress in adverse event surveillance technologies, data interpretation, and signal identification, which aids in the swift discovery of adverse drug reactions following market release. As an illustration, in February 2024, data from the Llywodraeth Cymru Welsh Government, a UK-based governmental body, indicated that in 2022, Wales channeled £1.0 billion ($1.25 billion) into Business Expenditure on Research and Development (BERD), representing 1.9% of the collective UK spending in this sector. Consequently, the rise in research and development operations has underpinned the expansion of the pharmacovigilance market.

What Are The Core Segmentation Criteria In The Pharmacovigilance Market?

The pharmacovigilance market covered in this report is segmented –

1) By Type: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining

2) By Service Provider: In-House, Contract Outsourcing

3) By Process Flow: Case Data Management, Signal Detection, Risk Management System

4) By Clinical Trial Phases: Preclinical, Phase I, Phase II, Phase III, Phase IV

5) By End User: Hospitals, Pharmaceutical Companies, Other End Users

Subsegments:

1) By Spontaneous Reporting: Individual Case Safety Reports (ICSRs), Voluntary Reporting Systems, Case Reports From Healthcare Professionals

2) By Intensified ADR Reporting: Active Surveillance Programs, Enhanced Monitoring In Clinical Trials, Risk Minimization Strategies

3) By Targeted Spontaneous Reporting: Reporting For Specific Drug Classes, Condition-Specific Reporting, Focused Surveillance Programs

4) By Cohort Event Monitoring: Prospective Cohort Studies, Retrospective Cohort Studies, Longitudinal Studies

5) By EHR Mining: Data Extraction From Electronic Health Records, Signal Detection Through EHR Analysis, Integration Of EHR Data With Pharmacovigilance Systems

Which Emerging Trends Are Reshaping The Pharmacovigilance Market Landscape?

Companies operating within the pharmacovigilance market are increasingly leveraging artificial intelligence (AI) to boost their operational effectiveness. AI is instrumental in enhancing both the efficiency and accuracy of pharmacovigilance processes, ultimately leading to improved patient outcomes. By deploying AI, pharmaceutical enterprises can streamline their workflows, optimize data management, and accelerate drug discovery, concurrently reducing costs and elevating safety standards. As an illustration, in August 2024, the Government of India introduced the Adverse Drug Reaction Monitoring System (ADRMS) software, launched by the Minister of Health & Family Welfare and Minister of Chemicals and Fertilizers. This pharmacovigilance software simplifies the collection and analysis of adverse events associated with medicines and medical devices, making the reporting procedure more accessible for both consumers and healthcare professionals. This endeavor significantly fortifies India’s pharmacovigilance infrastructure by ensuring a more comprehensive capture of safety data and augmenting drug safety monitoring. The ADRMS aims to enhance the efficacy of drug safety oversight and compliance with established standards, thereby contributing to India’s position as a leader in the global pharmaceutical industry.

Which Players Are Shaping The Competitive Landscape Of The PharmacovigilanceXX Market?

Major companies operating in the pharmacovigilance market include IQVIA, Cognizant, ICON Plc, Accenture plc, PAREXEL International Corporation., United BioSource LLC, ArisGlobal, Quanticate, Wipro Limited, Linical Americas, Novotech CRO, Wuxi Apptec, Simcere Pharmaceutical Group, Lee’s Pharmaceutical Holdings, Luye Pharma Group, EXTEDO, Arriello, PrimeVigilance, Axios International, C3i Solutions, Alcon, Secure AI Labs, OmniSol dot Tech, Canna Call Company, Veripad, Prevnos Inc., Lifescient, Inc, BeiGene, QuintilesIMS, Labcorp Drug Development, Pharmaceutical Product Development Inc., PRA Health Sciences, Synowledge LLC, RAPAhub, illuminate health, Invenio Medical, ClinChoice Inc., MSD, Novasyte, Fortrea Holdings Inc, Syneos Health Clinical, Zoetis Inc., Telerx Marketing Inc., Gilead Sciences, Inc., Elanco, Abbott Laboratories, Spimaco, Teva Pharmaceutical Industries Ltd.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report

What Regional Trends Are Shaping Growth In The Pharmacovigilance Market?

North America was the largest region in the pharmacovigilance market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast region. The regions covered in the pharmacovigilance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=5928&type=smp

Browse Through More Reports Similar to the Global Pharmacovigilance Market 2025, By The Business Research Company

Pharmaceutical Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-global-market-report

Pharmaceutical Excipient Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-excipient-global-market-report

Pharma Microbiology Testing Kits Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharma-microbiology-testing-kits-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Pharmacovigilance Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The pharmacovigilance market size has shown significant recent expansion. It is projected to increase from $8.58 billion in 2024 to $9.64 billion in 2025, at a compound annual growth rate (CAGR) of 12.4%. This historical growth can be attributed to the rising incidence of adverse drug reactions (ADRs), heightened research and development (R&D) activities, accelerating drug development rates, a stronger focus on personalized medicine, and the increasing prevalence of chronic diseases.

The pharmacovigilance market is projected to experience substantial expansion over the upcoming years, with its valuation expected to reach $15.5 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.6%. This anticipated growth throughout the forecast period is primarily fueled by escalating healthcare expenditure, increasing governmental assistance, and the growing elderly population. Significant trends during this period are expected to involve a rise in investments, the adoption of artificial intelligence, the utilization of cutting-edge platforms, the deployment of innovative cloud-based systems, and strategic mergers and acquisitions.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5928&type=smp

What Are The Drivers Pushing New Developments In The Pharmacovigilance Market?

The expanding scope of research and development activities is anticipated to propel the pharmacovigilance market. By allocating resources to R&D, pharmaceutical companies can formulate innovative drugs characterized by improved safety profiles. Rigorous preclinical and clinical assessments conducted during the drug development phase enable the timely identification of potential safety concerns, thus allowing for the deployment of appropriate risk mitigation strategies. Moreover, R&D efforts contribute to advancements in technologies for monitoring adverse events, analyzing data, and detecting signals, thereby aiding the early detection of adverse drug reactions in the post-marketing phase. For instance, in February 2024, the Llywodraeth Cymru Welsh Government, a UK-based government agency, stated that in 2022, Wales invested £1.0 billion ($1.25 billion) in Business Expenditure on Research and Development (BERD), which constituted 1.9% of the total UK expenditure in this domain. Therefore, the heightened research and development activities have supported the expansion of the pharmacovigilance market.

How Is The Pharmacovigilance Market Classified Into Different Segments?

The pharmacovigilance market covered in this report is segmented –

1) By Type: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining

2) By Service Provider: In-House, Contract Outsourcing

3) By Process Flow: Case Data Management, Signal Detection, Risk Management System

4) By Clinical Trial Phases: Preclinical, Phase I, Phase II, Phase III, Phase IV

5) By End User: Hospitals, Pharmaceutical Companies, Other End Users

Subsegments:

1) By Spontaneous Reporting: Individual Case Safety Reports (ICSRs), Voluntary Reporting Systems, Case Reports From Healthcare Professionals

2) By Intensified ADR Reporting: Active Surveillance Programs, Enhanced Monitoring In Clinical Trials, Risk Minimization Strategies

3) By Targeted Spontaneous Reporting: Reporting For Specific Drug Classes, Condition-Specific Reporting, Focused Surveillance Programs

4) By Cohort Event Monitoring: Prospective Cohort Studies, Retrospective Cohort Studies, Longitudinal Studies

5) By EHR Mining: Data Extraction From Electronic Health Records, Signal Detection Through EHR Analysis, Integration Of EHR Data With Pharmacovigilance Systems

What Are The Latest Industry Trends Transforming The Pharmacovigilance Market?

Organizations in the pharmacovigilance industry are directing their attention towards artificial intelligence (AI) to enhance operational efficiency. AI is capable of improving the effectiveness and accuracy of pharmacovigilance activities, ultimately resulting in improved patient outcomes. By leveraging AI, pharmaceutical companies can streamline their processes, better manage data, and accelerate drug discovery, while simultaneously reducing costs and increasing safety. For instance, in August 2024, the Government of India introduced the Adverse Drug Reaction Monitoring System (ADRMS) software, launched by the Minister of Health & Family Welfare and Minister of Chemicals and Fertilizers. This pharmacovigilance software assists in the collection and analysis of adverse events associated with medications and medical devices, thereby simplifying the reporting process for both consumers and healthcare professionals. This initiative considerably strengthens India’s pharmacovigilance infrastructure by ensuring a more comprehensive capture of safety data and improving the monitoring of drug safety. The ADRMS aims to enhance the efficiency of drug safety oversight and compliance with standards, helping to position India as a leader in the global pharmaceutical industry.

Who Are The Top Performing Companies In The Pharmacovigilance Market In Recent Years?

Major companies operating in the pharmacovigilance market include IQVIA, Cognizant, ICON Plc, Accenture plc, PAREXEL International Corporation., United BioSource LLC, ArisGlobal, Quanticate, Wipro Limited, Linical Americas, Novotech CRO, Wuxi Apptec, Simcere Pharmaceutical Group, Lee’s Pharmaceutical Holdings, Luye Pharma Group, EXTEDO, Arriello, PrimeVigilance, Axios International, C3i Solutions, Alcon, Secure AI Labs, OmniSol dot Tech, Canna Call Company, Veripad, Prevnos Inc., Lifescient, Inc, BeiGene, QuintilesIMS, Labcorp Drug Development, Pharmaceutical Product Development Inc., PRA Health Sciences, Synowledge LLC, RAPAhub, illuminate health, Invenio Medical, ClinChoice Inc., MSD, Novasyte, Fortrea Holdings Inc, Syneos Health Clinical, Zoetis Inc., Telerx Marketing Inc., Gilead Sciences, Inc., Elanco, Abbott Laboratories, Spimaco, Teva Pharmaceutical Industries Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report

Which Region Currently Holds The Largest Share Of The Pharmacovigilance Market?

North America was the largest region in the pharmacovigilance market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast region. The regions covered in the pharmacovigilance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Pharmacovigilance Market Report:

https://www.thebusinessresearchcompany.com/customise?id=5928&type=smp

Browse Through More Reports Similar to the Global Pharmacovigilance Market 2025, By The Business Research Company

Pharmaceutical Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-global-market-report

Pharmaceutical Excipient Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-excipient-global-market-report

Pharma Microbiology Testing Kits Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharma-microbiology-testing-kits-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Is The Pharmacovigilance Market Expected To Grow In Terms Of Size?

Over the past few years, the pharmacovigilance market size has witnessed substantial growth. It is predicted that this market will expand from $8.58 billion in 2024 to reach $9.64 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 12.4%. Factors contributing to historical growth include the rising cases of adverse drug reactions (ADRs), the surge in research and development (R&D) activities, the increasing rate of drug development, a heightened emphasis on personalized medicine, and an escalating prevalence of chronic diseases.

The market size of pharmacovigilance is set to witness substantial expansion in the coming years and is projected to reach “$15.5 billion by 2029, with a compound annual growth rate (CAGR) of 12.6%. The significant growth anticipated during this period is due to factors such as increased healthcare spending, enhanced government assistance, and an aging population. Prevailing trends for the forecast period encompass escalated investments, utilization of artificial intelligence, adoption of inventive platforms, implementation of cutting-edge cloud-based systems, and strategic collaborations and acquisitions.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5928&type=smp

What Market Forces Are Contributing To The Growth Of The Pharmacovigilance Market?

The growth of the pharmacovigilance market is fuelled by escalating investment in research and development activities. The enlargement of new and inventive drugs with enhanced safety levels is made possible by this R&D expenditure. Comprehensive examinations during the developmental phase of the drug enable the early recognition and management of prospective safety risks. Furthermore, progress in technology for adverse event tracing, data scrutinizing, and signal detection catalysed by R&D initiatives facilitates the timely discovery of adverse drug responses in the post-marketing phase. For example, as reported by the Llywodraeth Cymru Welsh Government, a government agency in the UK, in February 2024, £1.0 billion ($1.25 billion), representing 1.9% of the total UK’s research and development expenditure was invested by Wales on Business Expenditure on Research and Development (BERD) in 2022. Consequently, the heightened research activities significantly contributed to the expansion of the pharmacovigilance market.

What Are The Primary Segmentation Parameters In The Pharmacovigilance Market?

The pharmacovigilance market covered in this report is segmented –

1) By Type: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining

2) By Service Provider: In-House, Contract Outsourcing

3) By Process Flow: Case Data Management, Signal Detection, Risk Management System

4) By Clinical Trial Phases: Preclinical, Phase I, Phase II, Phase III, Phase IV

5) By End User: Hospitals, Pharmaceutical Companies, Other End Users

Subsegments:

1) By Spontaneous Reporting: Individual Case Safety Reports (ICSRs), Voluntary Reporting Systems, Case Reports From Healthcare Professionals

2) By Intensified ADR Reporting: Active Surveillance Programs, Enhanced Monitoring In Clinical Trials, Risk Minimization Strategies

3) By Targeted Spontaneous Reporting: Reporting For Specific Drug Classes, Condition-Specific Reporting, Focused Surveillance Programs

4) By Cohort Event Monitoring: Prospective Cohort Studies, Retrospective Cohort Studies, Longitudinal Studies

5) By EHR Mining: Data Extraction From Electronic Health Records, Signal Detection Through EHR Analysis, Integration Of EHR Data With Pharmacovigilance Systems

Which Emerging Trends Are Reshaping The Pharmacovigilance Market Landscape?

Pharmacovigilance market players are turning their attention towards artificial intelligence (AI) to bolster efficiency. AI has the potential to enhance both the effectiveness and precision of pharmacovigilance tasks, which could lead to superior patient results. Use of AI allows pharmaceutical companies to streamline operations, enhance data handling, speed up drug discovery, while concurrently lowering expenses and amplifying safety. For example, in August 2024, the Indian Government initiated the Adverse Drug Reaction Monitoring System (ADRMS) software, launched by the Minister of Health & Family Welfare and the Minister of Chemicals and Fertilizers. This bespoke pharmacovigilance software simplifies the gathering and evaluation of adverse incidents relating to drugs and medical apparatus, making the reporting protocol less complex for both patients and healthcare professionals. This drive notably bolsters India’s pharmacovigilance foundations by ensuring a more complete acquisition of safety findings and bolstering medication safety observation. The ADRMS is geared towards enhancing the effectiveness of drug safety management and compliance to norms, aiding India’s progression as a frontrunner in the international pharmaceutical sector.

Which Players Are Shaping The Competitive Landscape Of The Pharmacovigilance Market?

Major companies operating in the pharmacovigilance market include IQVIA, Cognizant, ICON Plc, Accenture plc, PAREXEL International Corporation., United BioSource LLC, ArisGlobal, Quanticate, Wipro Limited, Linical Americas, Novotech CRO, Wuxi Apptec, Simcere Pharmaceutical Group, Lee’s Pharmaceutical Holdings, Luye Pharma Group, EXTEDO, Arriello, PrimeVigilance, Axios International, C3i Solutions, Alcon, Secure AI Labs, OmniSol dot Tech, Canna Call Company, Veripad, Prevnos Inc., Lifescient, Inc, BeiGene, QuintilesIMS, Labcorp Drug Development, Pharmaceutical Product Development Inc., PRA Health Sciences, Synowledge LLC, RAPAhub, illuminate health, Invenio Medical, ClinChoice Inc., MSD, Novasyte, Fortrea Holdings Inc, Syneos Health Clinical, Zoetis Inc., Telerx Marketing Inc., Gilead Sciences, Inc., Elanco, Abbott Laboratories, Spimaco, Teva Pharmaceutical Industries Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report

What Are The Emerging Regional Trends Driving The Pharmacovigilance Market?

North America was the largest region in the pharmacovigilance market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast region. The regions covered in the pharmacovigilance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=5928&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global Pharmacovigilance Market Valued at Present and by 2029?

In recent years, the size of the pharmacovigilance market has seen rapid expansion. It is predicted to increase from $8.58 billion in 2024 to $9.64 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 12.4%. The past growth trend can be traced back to factors such as rising cases of adverse drug reactions (ADRs), heightened research and development (R&D) initiatives, increased rates of drug development, an intensified emphasis on personalized medicine, and a growing occurrence of chronic diseases.

The market size of pharmacovigilance is projected to experience significant expansion in the upcoming years. The market is anticipated to escalate to “$15.5 billion by 2029 with a compound annual growth rate (CAGR) of 12.6%. This predicted growth within the forecast period can be credited to the escalating healthcare costs, additional government assistance, and the aging populace. The forecast period will also witness such major trends as increased investments, utilization of artificial intelligence, the employment of innovative platforms, the incorporation of innovative cloud-based systems, and tactical mergers and acquisitions.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5928&type=smp

#What Drivers Are Influencing Growth In The Pharmacovigilance Market?

The pharmacovigilance market is being propelled by escalating activities in research and development. As pharmaceutical companies boost their R&D investment, they are better positioned to create innovative, safer drugs. Comprehensive preclinical and clinical evaluations during the drug creation process facilitate the early identification of possible safety risks, enabling the execution of suitable risk reduction strategies. Furthermore, advancements in adverse event observation, data scrutiny, and signal identification technologies aided by R&D efforts enable adverse drug effects to be detected promptly during the post-market phase. For instance, Llywodraeth Cymru Welsh Government, a UK government agency, reported in February 2024 that Wales invested £1.0 billion ($1.25 billion) in Business Expenditure on Research and Development (BERD) in 2022. This accounted for 1.9% of the entire UK expenditure in this field. Consequently, the growth of the pharmacovigilance market has been sustained by the increasing activities in research and development.

The pharmacovigilance market covered in this report is segmented –

1) By Type: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining

2) By Service Provider: In-House, Contract Outsourcing

3) By Process Flow: Case Data Management, Signal Detection, Risk Management System

4) By Clinical Trial Phases: Preclinical, Phase I, Phase II, Phase III, Phase IV

5) By End User: Hospitals, Pharmaceutical Companies, Other End Users

Subsegments:

1) By Spontaneous Reporting: Individual Case Safety Reports (ICSRs), Voluntary Reporting Systems, Case Reports From Healthcare Professionals

2) By Intensified ADR Reporting: Active Surveillance Programs, Enhanced Monitoring In Clinical Trials, Risk Minimization Strategies

3) By Targeted Spontaneous Reporting: Reporting For Specific Drug Classes, Condition-Specific Reporting, Focused Surveillance Programs

4) By Cohort Event Monitoring: Prospective Cohort Studies, Retrospective Cohort Studies, Longitudinal Studies

5) By EHR Mining: Data Extraction From Electronic Health Records, Signal Detection Through EHR Analysis, Integration Of EHR Data With Pharmacovigilance Systems

What Upcoming Trends Are Expected To Impact The Pharmacovigilance Market Globally?

Pharmaceutical companies in the pharmacovigilance market are turning their attention to artificial intelligence (AI) as a means to enhance efficiency. The use of AI can heighten the precision and effectiveness of pharmacovigilance activities, ultimately resulting in improved patient care. Integration of AI enables pharmaceutical firms to better optimize processes, enhance data management, and fast-track drug finding, all while slashing costs and augmenting safety. For instance, in August 2024, the Indian Government launched the Adverse Drug Reaction Monitoring System (ADRMS) software – a pharmacovigilance software pioneered by the Ministry of Health & Family Welfare and Ministry of Chemicals and Fertilizers. This software makes the process of gathering and interpreting adverse occurrences related to medicines and medical devices easier for consumers and healthcare professionals alike. This move significantly boosts India’s pharmacovigilance framework by assuring a more thorough collection of safety data and improving medication safety monitoring. The ADRMS is designed to enhance the efficiency of drug safety management and adherence to standards, granting India a leadership position in the international pharmaceutical sector.

Which Companies Play A Key Role In The Development Of The Pharmacovigilance Market?

Major companies operating in the pharmacovigilance market include IQVIA, Cognizant, ICON Plc, Accenture plc, PAREXEL International Corporation., United BioSource LLC, ArisGlobal, Quanticate, Wipro Limited, Linical Americas, Novotech CRO, Wuxi Apptec, Simcere Pharmaceutical Group, Lee’s Pharmaceutical Holdings, Luye Pharma Group, EXTEDO, Arriello, PrimeVigilance, Axios International, C3i Solutions, Alcon, Secure AI Labs, OmniSol dot Tech, Canna Call Company, Veripad, Prevnos Inc., Lifescient, Inc, BeiGene, QuintilesIMS, Labcorp Drug Development, Pharmaceutical Product Development Inc., PRA Health Sciences, Synowledge LLC, RAPAhub, illuminate health, Invenio Medical, ClinChoice Inc., MSD, Novasyte, Fortrea Holdings Inc, Syneos Health Clinical, Zoetis Inc., Telerx Marketing Inc., Gilead Sciences, Inc., Elanco, Abbott Laboratories, Spimaco, Teva Pharmaceutical Industries Ltd.

https://www.thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report

What Are The Key Regional Developments Shaping The Pharmacovigilance Market?

North America was the largest region in the pharmacovigilance market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast region. The regions covered in the pharmacovigilance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=5928&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model